Latest Insider Transactions at Liquidia Corp (LQDA)
This section provides a real-time view of insider transactions for Liquidia Corp (LQDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Liquidia Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Liquidia Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 27
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
445
-0.25%
|
$6,230
$14.2 P/Share
|
|
Jan 21
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,445
-0.9%
|
$31,785
$13.0 P/Share
|
|
Jan 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
16,393
-2.78%
|
$180,323
$11.78 P/Share
|
|
Jan 14
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,343
-2.15%
|
$245,773
$11.78 P/Share
|
|
Jan 14
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,809
-2.6%
|
$52,899
$11.78 P/Share
|
|
Jan 14
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
23,370
-5.5%
|
$257,070
$11.78 P/Share
|
|
Jan 14
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,362
-3.74%
|
$91,982
$11.78 P/Share
|
|
Jan 14
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,249
-2.26%
|
$68,739
$11.78 P/Share
|
|
Jan 11
2025
|
Russell Schundler General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
102,543
+14.81%
|
-
|
|
Jan 11
2025
|
Roger Jeffs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
229,327
+18.05%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+2.07%
|
-
|
|
Jan 11
2025
|
Jason Adair Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,895
+25.47%
|
-
|
|
Jan 11
2025
|
Michael Kaseta CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
112,797
+20.97%
|
-
|
|
Jan 11
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,729
+23.75%
|
-
|
|
Jan 11
2025
|
Rajeev Saggar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,780
+20.6%
|
-
|
|
Dec 02
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,091
-0.35%
|
$12,001
$11.51 P/Share
|
|
Dec 02
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.35%
|
$6,006
$11.51 P/Share
|
|
Dec 02
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.38%
|
$5,005
$11.51 P/Share
|
|
Dec 02
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
1,063
-0.22%
|
$11,693
$11.51 P/Share
|
|
Nov 30
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,343
+0.74%
|
-
|
|
Nov 30
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
Nov 30
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+1.29%
|
-
|
|
Nov 30
2024
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,343
+0.48%
|
-
|
|
Oct 28
2024
|
Jason Adair Chief Business Officer |
BUY
Open market or private sale
|
Direct |
459
+0.39%
|
$5,049
$11.31 P/Share
|
|
Oct 18
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,526
-1.22%
|
$27,786
$11.19 P/Share
|
|
Oct 14
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,527
-0.99%
|
$16,797
$11.11 P/Share
|
|
Oct 14
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,260
-1.08%
|
$24,860
$11.11 P/Share
|
|
Oct 14
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
2,576
-0.53%
|
$28,336
$11.11 P/Share
|
|
Oct 14
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,146
-0.96%
|
$12,606
$11.11 P/Share
|
|
Oct 14
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,053
-0.98%
|
$88,583
$11.11 P/Share
|
|
Oct 14
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
3,892
-1.24%
|
$42,812
$11.11 P/Share
|
|
Oct 11
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+3.16%
|
-
|
|
Sep 12
2024
|
Paul B Manning Director |
BUY
Open market or private purchase
|
Indirect |
337,078
+29.23%
|
$2,696,624
$8.9 P/Share
|
|
Sep 12
2024
|
Caligan Partners LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,123,595
+12.16%
|
$8,988,760
$8.9 P/Share
|
|
Sep 03
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
710
-0.15%
|
$6,390
$9.5 P/Share
|
|
Sep 03
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.39%
|
$4,095
$9.5 P/Share
|
|
Sep 03
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,079
-0.34%
|
$9,711
$9.5 P/Share
|
|
Sep 03
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.35%
|
$4,914
$9.5 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+2.1%
|
$1,350,000
$9.51 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
SELL
Open market or private sale
|
Indirect |
150,000
-2.14%
|
$1,350,000
$9.51 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
SELL
Other acquisition or disposition
|
Indirect |
3,440,948
-32.97%
|
-
|
|
Aug 30
2024
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.48%
|
-
|
|
Aug 30
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+1.33%
|
-
|
|
Aug 30
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.74%
|
-
|
|
Aug 30
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
Jul 26
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,833
-1.59%
|
$20,163
$11.44 P/Share
|
|
Jul 19
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,873
-0.89%
|
$20,603
$11.13 P/Share
|
|
Jul 12
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,528
-1.0%
|
$18,336
$12.53 P/Share
|
|
Jul 12
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,053
-0.97%
|
$96,636
$12.53 P/Share
|
|
Jul 12
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,470
-0.69%
|
$17,640
$12.53 P/Share
|